A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil
Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Lung Cancer
Intervention: Armodafinil (Drug); Placebo (Other); Minocycline (Drug); Questionnaires (Behavioral)
Status: Active, not recruiting
Sponsored by: M.D. Anderson Cancer Center
Official(s) and/or principal investigator(s):
Zhongxing Liao, MD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center
The goal of this clinical research study is to compare armodafinil and minocycline when
given alone or in combination to learn which is better for controlling symptoms, such as the
side effects of chemoradiation, when given to treat lung cancer.
Official title: A Pilot Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
Primary outcome: 10-week AUC for 5 targeted symptoms
The Study Drugs:
Armodafinil is designed to prevent excessive sleepiness.
Minocycline is an antibiotic. Minocycline has been shown to interrupt cytokine production,
which may help to reduce multiple symptoms.
A placebo is not a drug. It looks like the study drug but is not designed to treat any
disease or illness. It is designed to be compared with a study drug to learn if the study
drug has any real effect.
If you agree to take part in this study, you will be randomly assigned (as in the roll of
dice) to join 1 of 4 groups.
- Group 1 will take armodafinil and a placebo.
- Group 2 will take minocycline and a placebo.
- Group 3 will take armodafinil and minocycline.
- Group 4 will take placebos alone.
Neither you nor the study staff you will see in the clinic will know if you are receiving
the study drug(s) and/or the placebo(s). However, if needed for your safety, the study
staff will be able to find out which study drug you are receiving.
If needed, during this study, you may receive standard care by your treating doctors.
Study Drug Administration:
You will take the study drug(s)/placebos every day for 10 weeks. You should take the
drug(s)/placebo(s) with a full glass of water. If you get an upset stomach, take them with
You will be given pamphlets with more information about how to take the study
You should bring your study drug/placebo capsules to the clinic every study visit.
Completing the Symptom Questionnaire:
Throughout the study, you will be asked to complete the symptom questionnaire. You will be
asked about symptoms from therapy you may be experiencing and how they may be interfering
with your daily activities. The study staff will either meet you during your regular clinic
visit or call you at your home at a time that is convenient for you. In the clinic, you
will complete the questionnaire by paper and pen, or by entering your answers into an
electronic tablet computer. On the phone, study staff will ask you the questions and record
your answers on paper or enter them into a computer. You will complete the symptom
questionnaire before you begin chemoradiation and then 1 time a week during Weeks 1-16 of
the study. The symptom questionnaire will take up to 5 minutes to complete.
Before you begin chemoradiation:
- You will complete 4 questionnaires about pain and other symptoms, your mood, and your
quality of life. Completing all 4 of the questionnaires will take about 15 minutes.
- If you are able to become pregnant, you will have a urine pregnancy test. The study
staff will give you the pregnancy test kit at your scheduled visit, and will review and
record the results of the test before you can pick up the study drugs from the
pharmacy. The pregnancy test will be repeated at weeks 1, 4, 7, and 12 (or at the first
follow-up clinic visit post-treatment) and 30 days after the study drugs are stopped .
During the last week of chemoradiation (about Week 7):
- You will complete 3 questionnaires about your symptoms, mood, and quality of life. These
questionnaires will take about 10 minutes total to complete.
After about Week 7, the study staff will call you 1 time a week to check on you until Week
10. This phone call should last only a few minutes. If you have had several side effects
from chemoradiation, this phone call may take longer.
About Week 12 (or at the first routine follow-up clinic visit post-treatment):
- You will complete the 3 questionnaires about your symptoms, mood, and quality of life.
- If you were smoking at the beginning of the study, you will complete a questionnaire
that asks if you stopped smoking any time during the study. This will take a few
minutes to complete.
- You will be asked to complete another questionnaire that asks about your satisfaction
with the study drug(s). This will take a few minutes.
Length of Study:
You will be on study for about 16 weeks. You will take the study drug(s) for 10 weeks and
complete the symptom survey until Week 16. You will be taken off study early if you have
intolerable side effects.
This is an investigational study. Armodafinil is FDA approved and commercially available
for the treatment of excessive sleepiness. Minocycline is FDA approved and commercially
available for the treatment of bacterial infections. The use of these drugs to help reduce
chemoradiation symptoms is investigational.
Up to 12 patients will take part in this study. All will be enrolled at MD Anderson.
Minimum age: 18 Years.
Maximum age: N/A.
1. Patients with a pathologically proven diagnosis of NSCLC and consented to concurrent
chemoradiation therapy at MD Anderson.
2. Patients > or =18 years old
3. Patients who will receive chemoradiation with platinum/taxane-based chemotherapy and
with a total radiation dose of > 50 Gy, per treating physician's assessment
4. Patients who speak English or Spanish (due to the novel research and its complexity,
we are only accruing English or Spanish-speaking patients to the protocol)
5. Patients must be willing and able to review, understand, and provide written consent
before starting therapy
1. Patients who are taking medications or have conditions that potentially preclude use
of any study medications or interventions, as determined by the treating physician
2. Patients who are enrolled in other symptom management or treatment clinical trials
3. Patients currently taking methylphenidate and/or dextroamphetamine.
4. Patients with a history of clinically significant cutaneous drug reaction, or a
history of clinically significant hypersensitivity reaction, including multiple
allergies or drug reaction as documented in the patient medical records
5. Patients with pre-existing psychosis or bipolar disorder.
6. Patients with pre-existing renal impairment: The screening cut off for serum
creatinine >1. 5 times ULN, according to MD Anderson testing standards, will be done
by the oncologist to qualify for CXRT.
7. Patients with pre-existing hepatic impairment: The screening for total bilirubin >1. 5
times ULN will be done by the oncologist to qualify for CXRT. The screening for > 2
times the upper limit of normal hepatotoxicity, alkaline phosphatase (ALP) and
alanine aminotransferase (ALT) (and aspartate aminotransferase [AST] if it is ordered
and available in the medical records) will be done by the oncologist to qualify for
8. Patients with pre-existing Tourette's syndrome.
9. Patients with hypersensitivity to any tetracyclines.
10. Patients who are pregnant. Pregnancy will be confirmed by negative urine test. Study
staff will provide the pregnancy kits to women and make sure the results are known
and recorded in the follow-up notes in Clinic Station before additional study drug
prescriptions are filled by the Pharmacy
11. Patients with uncontrolled cardiac disease, within the past six months history of
left ventricular hypertrophy, myocardial infarction, and history of mitral valve
prolapse syndrome with previous CNS stimulant use .
12. Patients taking medicines that are strong CYP3A4 inhibitors or inducers (including
conivaptan, indinavir, nelfinavir, ritonavir, nefazodone, and phenytoin), or strong
CYP2C19 inhibitors (including citalopram and clopidogrel) .
13. Patients on vitamin K antagonist warfarin.
Locations and Contacts
University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States
University of Texas MD Anderson Cancer Center Website
Starting date: July 2011
Last updated: March 9, 2015